Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

77265

	registered interest
	date	10/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Lyme Disease
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government whether, in December 2011, the Clinical Pathology Accreditation Service was made aware of modifications by the Health Protection Agency’s Lyme Borreliosis Unit to the Trinity Biotech immunoblot kit to be used for testing human cerebrospinal fluid.
	tabling member printed	The Countess of Mar
	uin	HL999
	answer	answer is ministerial correction date of answer 24/07/2014 answer text <p>The former Health Protection Agency's Lyme Borreliosis Unit (HPA LBU) was accredited by Clinical Pathology Accreditation who had access to, and was able to review, all the standard operating procedures of the unit.</p><p> </p><p>The Trinity Biotech Lyme Western Blot is a qualitative in vitro assay for the detection of Immunoglobulin (IgG or IgM) antibodies in human samples against specific antigens/proteins of <em>Borrelia afzelii, Borrelia garinii and Borrelia burgdorferi</em>. The Trinity Biotech Lyme Western Blot is intended as a confirmatory assay for use in testing human samples which have been previously found to be positive or equivocal using an Enzyme Immunoassay and Immunofluroescent Assay or other appropriate screening method. Positive second-tier results are supportive evidence of infection with <em>B. burgdorferi</em>. The diagnosis of Lyme disease should be made based on history and symptoms (such as erythema migrans), and other laboratory data, in addition to the presence of antibodies to <em>B. burgdorferi</em>. The Trinity Biotech blot has been in use since 2007 by the former HPA’s LBU for testing cerebrospinal fluid (CSF) and proved very reliable. This technique has also been in use widely across Europe during this period as a diagnostic test using CSF as a sample to support the diagnosis of neuroborreliosis.</p> answering member printed Earl Howe question first answered 24/07/2014 12:32:59 answering member 2000 label Biography information for Earl Howe
	tabling member	1861 label Biography information for The Countess of Mar

77264

	registered interest
	date	10/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Lyme Disease
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government when the testing of the cerebrospinal fluid of patients suspected of having Lyme disease using the Trinity Biotech kit at the Health Protection Agency’s Lyme Borreliosis Unit began; how many patients' samples were tested in that way; and how many patients were recorded as being positive over that period of time.
	tabling member printed	The Countess of Mar
	uin	HL998
	answer	answer is ministerial correction date of answer 24/07/2014 answer text <p>The Trinity Biotech blot has been in use since 2007 by the former Health Protection Agency's Lyme Borreliosis Unit for testing cerebrospinal fluid (CSF) and proved very reliable. It has also been used in this way by other laboratories in Europe. However, CSF antibodies will not be present if there is no evidence of any other antibodies in the serum. Data is not collected centrally on specific samples from patients as the final diagnosis is made by the clinician on the basis of the test results and the clinical presentation.</p> answering member printed Earl Howe question first answered 24/07/2014 12:31:17 answering member 2000 label Biography information for Earl Howe
	tabling member	1861 label Biography information for The Countess of Mar

967478

	registered interest
	date	04/09/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Benzodiazepines: Misuse
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether they will establish a public inquiry into the harmful effects of prescribed benzodiazepine drug dependence over the last 50 years.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL9971
	answer	answer is ministerial correction date of answer 17/09/2018 answer text <p>The Parliamentary under Secretary of State (Steve Brine MP) commissioned Public Health England (PHE) to review the evidence for dependence on, and withdrawal from, prescribed medicines. The review was launched in January 2018 and is due to report in spring 2019 and we await its findings. It is the responsibility of local authorities to commission services, such as the provision of withdrawal centres for addiction to prescribed medicines, to meet assessed local need. The Government currently has no plans to increase the number of these centres.</p><p>The Government has no plans to introduce a separate national helpline to support people affected by prescribed drug dependence. Help and advice on prescribed drug dependence is already available from the 111 helpline or NHS Choices. People who feel that they might be dependent on either prescribed or over the counter medicines should seek help from a health professional in the first instance (such as a general practitioner or pharmacist).</p><p>PHE’s review includes prescribed benzodiazepine drug dependence but will not consider evidence further back than 10 years ago. There are no plans to establish a public inquiry into prescribed benzodiazepine drug dependence.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL9967 HL9968 HL9969 question first answered 17/09/2018 14:06:06 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

967477

	registered interest
	date	04/09/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Prescription Drugs: Misuse
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of the effectiveness of substance misuse services and, in particular, whether they may bring patients off the use of prescribed medicines too quickly leaving many in a damaged state.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL9970
	answer	answer is ministerial correction date of answer 17/09/2018 answer text <p>Public Health England (PHE) carried out an extensive review of the effectiveness of drug treatment in England. The review gives policy makers and local areas an objective assessment of what drug treatment outcomes are achievable, and compares outcomes in England to the evidence and to other drug treatment systems. <em>An evidence review of outcomes that can be expected of drug misuse treatment in England</em> is attached.</p><p>Local authorities are responsible for assessing local need for substance misuse treatment and commissioning services to meet these needs. This includes making sure the services follow clinical guidelines in treating people who have dependence problems. The United Kingdom drug treatment clinical guidelines set out guidance for clinicians in managing withdrawal for patients from prescribed medicines.</p><p>PHE is undertaking a review of the evidence for dependence on, and withdrawal from, prescribed medicines. The review will bring together the best available evidence on effective prevention and treatment of dependence, withdrawal and discontinuation syndrome for each drug category. The review is due to be published in spring 2019.</p> answering member printed Lord O'Shaughnessy question first answered 17/09/2018 13:57:58 answering member 4545 label Biography information for Lord O'Shaughnessy attachment 1 file name Drug Misuse Treatment in England Evidence Review of Outcomes review.pdf title Drug Misuse Treatment in England Evidence Review
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

386888

	registered interest
	date	01/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Amyloidosis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government which of the four phase 2 or 3 clinical trials for systemic amyloidosis approved since 2004 are still ongoing; and whether any of the trials have produced sufficient positive outcomes to encourage commercial development.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL997
	answer	answer is ministerial correction date of answer 14/07/2015 answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL995 HL996 question first answered 14/07/2015 15:34:29 answering member 127 label Biography information for Lord Prior of Brampton attachment 1 file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf title 2013-14 Annual Report
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

967476

	registered interest
	date	04/09/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Prescription Drugs: Misuse
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether they will ensure that in establishing a 24 hour helpline for people affected by prescribed medicines addiction they will also ensure that adequate services are in place to refer patients to.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL9969
	answer	answer is ministerial correction date of answer 17/09/2018 answer text <p>The Parliamentary under Secretary of State (Steve Brine MP) commissioned Public Health England (PHE) to review the evidence for dependence on, and withdrawal from, prescribed medicines. The review was launched in January 2018 and is due to report in spring 2019 and we await its findings. It is the responsibility of local authorities to commission services, such as the provision of withdrawal centres for addiction to prescribed medicines, to meet assessed local need. The Government currently has no plans to increase the number of these centres.</p><p>The Government has no plans to introduce a separate national helpline to support people affected by prescribed drug dependence. Help and advice on prescribed drug dependence is already available from the 111 helpline or NHS Choices. People who feel that they might be dependent on either prescribed or over the counter medicines should seek help from a health professional in the first instance (such as a general practitioner or pharmacist).</p><p>PHE’s review includes prescribed benzodiazepine drug dependence but will not consider evidence further back than 10 years ago. There are no plans to establish a public inquiry into prescribed benzodiazepine drug dependence.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL9967 HL9968 HL9971 question first answered 17/09/2018 14:06:06 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

967475

	registered interest
	date	04/09/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Prescription Drugs: Misuse
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what plans they have, if any, to increase the number of prescribed medicines withdrawal centres to cover the whole of England.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL9968
	answer	answer is ministerial correction date of answer 17/09/2018 answer text <p>The Parliamentary under Secretary of State (Steve Brine MP) commissioned Public Health England (PHE) to review the evidence for dependence on, and withdrawal from, prescribed medicines. The review was launched in January 2018 and is due to report in spring 2019 and we await its findings. It is the responsibility of local authorities to commission services, such as the provision of withdrawal centres for addiction to prescribed medicines, to meet assessed local need. The Government currently has no plans to increase the number of these centres.</p><p>The Government has no plans to introduce a separate national helpline to support people affected by prescribed drug dependence. Help and advice on prescribed drug dependence is already available from the 111 helpline or NHS Choices. People who feel that they might be dependent on either prescribed or over the counter medicines should seek help from a health professional in the first instance (such as a general practitioner or pharmacist).</p><p>PHE’s review includes prescribed benzodiazepine drug dependence but will not consider evidence further back than 10 years ago. There are no plans to establish a public inquiry into prescribed benzodiazepine drug dependence.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL9967 HL9969 HL9971 question first answered 17/09/2018 14:06:06 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

967474

	registered interest
	date	04/09/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Prescription Drugs: Misuse
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what plans they have to secure funding for existing prescribed medicines withdrawal centres.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL9967
	answer	answer is ministerial correction date of answer 17/09/2018 answer text <p>The Parliamentary under Secretary of State (Steve Brine MP) commissioned Public Health England (PHE) to review the evidence for dependence on, and withdrawal from, prescribed medicines. The review was launched in January 2018 and is due to report in spring 2019 and we await its findings. It is the responsibility of local authorities to commission services, such as the provision of withdrawal centres for addiction to prescribed medicines, to meet assessed local need. The Government currently has no plans to increase the number of these centres.</p><p>The Government has no plans to introduce a separate national helpline to support people affected by prescribed drug dependence. Help and advice on prescribed drug dependence is already available from the 111 helpline or NHS Choices. People who feel that they might be dependent on either prescribed or over the counter medicines should seek help from a health professional in the first instance (such as a general practitioner or pharmacist).</p><p>PHE’s review includes prescribed benzodiazepine drug dependence but will not consider evidence further back than 10 years ago. There are no plans to establish a public inquiry into prescribed benzodiazepine drug dependence.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL9968 HL9969 HL9971 question first answered 17/09/2018 14:06:06 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

967473

	registered interest
	date	04/09/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Prescription Drugs: Misuse
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether they will ensure that members of Parliament and members of the House of Lords will have an opportunity to meet with Public Health England to discuss the review of prescribed medicines addiction before it reports.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL9966
	answer	answer is ministerial correction date of answer 17/09/2018 answer text <p>Public Health England (PHE) is open to engagement with hon. Members and noble Lords on this issue.</p><p>PHE is also in regular contact with the All-Party Parliamentary Group on Prescribed Drug Dependence, including presenting at the group’s meetings in Parliament. We expect that this contact will continue.</p> answering member printed Lord O'Shaughnessy question first answered 17/09/2018 13:58:36 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

967472

	registered interest
	date	04/09/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health Visitors
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what continuous professional development health visitors are required to undertake to enable them to identify incipient and actual cases of ante-natal depression, post-natal depression, and other maternal mental health issues.
	tabling member printed	Baroness Hodgson of Abinger
	uin	HL9965
	answer	answer is ministerial correction date of answer 17/09/2018 answer text <p>Health visitors are part of the nursing profession and regulated by the Nursing and Midwifery Council (NMC). Health visitors are qualified and registered nurses or midwives who have undertaken an approved training programme in Specialist Community Public Health Nursing - Health Visiting.</p><p>The NMC has the general function of promoting high standards of education and coordinating all stages of education to ensure that health visitors are equipped with the knowledge, skills and attitudes essential for professional practice, including continuous professional development (CPD). The NMC set the standards of education and training for the nursing profession expected at undergraduate and postgraduate level and approve curricula set by individual higher education institutes. In so doing, they set out the knowledge, skills and behaviours that both postgraduate and undergraduate nurses must be able to demonstrate.</p><p>CPD is a term used to describe a number of different training and development activities which may be required for the purposes of professional practice in the National Health Service. The NMC requires 35 hours of CPD relevant to scope of practice in the three year period since registration was last renewed, or joining the register.</p><p>The NMC are in the process of rewriting their standards. For example, in the new pre-registration nursing standards the NMC specify that registrants must have proficiencies in identifying risk and vulnerability, in all settings and across the lifespan and would expect post-natal depression to be included in the curriculum.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL9964 question first answered 17/09/2018 13:50:13 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	4301 label Biography information for Baroness Hodgson of Abinger